Elsevier

Contraception

Volume 51, Issue 4, April 1995, Pages 221-224
Contraception

Original research article
Bone mass and long-term monophasic oral contraceptive treatment in young women

https://doi.org/10.1016/0010-7824(95)00036-AGet rights and content

Abstract

A prospective study has been designed to investigate bone metabolism in young women taking an oral monophasic contraceptive formulation (ethinylestradiol 20 μg + desogestrel 0.150 mg) over 5 years.

Healthy women (n = 200) between 19 and 22 years of age were divided into two groups. Group A received oral contraception, Group B did not receive any treatment. All the subjects underwent a bone mass density (BMD) evaluation at spinal level L2–L4 with Dexa (Norland XR-26) and a measurement of the serum alkaline phosphatase levels and urinary excretion of OH-proline at baseline and every 12 months over 5 years.

Our results demonstrated that Group A did not show any significant BMD change after 5 years of oral contraceptive treatment, while Group B demonstrated a significant increase (p <0.01) in the bone mass content at the end of the time of observation (+ 7.8% after 5 years). No significant changes were found in serum alkaline phosphatase levels and in urinary excretion of OH-proline at the end of the study in comparison with basal levels in both groups.

Our data suggested that long-term treatment with an oral monophasic contraceptive formulation (ethinylestradiol 20 μg + desogestrel 0.150 mg) did not modify the BMD but prevented the occurrence of the physiologic peak of bone mass in young women.

References (15)

There are more references available in the full text version of this article.

Cited by (0)

View full text